2017-18 Assessment - Cancer

What this data shows:

Assessment by the clinical panel for cancer based on the available CCG IAF indicators

How the data is gathered:

The panel has inspected the values for each of the available CCG IAF indicators for cancer and produced an overall assessment based on their values. The independent panel consists of experts in the field of cancer.

To produce the overall assessment: Indicators are banded using a method based on z-scores at 1.96 standard deviations. The patient experience indicator CCG is awarded a score of 0, 1 or 2, based on the value of its z-score. The early diagnosis and one-year survival indicators are awarded scores of 0, 0.75, 1.25 or 2, with a distinction in the intermediate bands between CCGs for which their score is above the national trajectory for the national ambition, that get a score of 1.25, and those for which their score is below it, that get a score of 0.75. For he 62-day indicator a score of 0, 0.75, 1.25 or 2 is awarded, with a distinction in the intermediate bands between CCGs that achieve the national standard of 85%, that get a score of 1.25, and those that don’t, that get a score of 0.75.

The methodology used to calculate an overall assessment rating is described in detail at: https://www.england.nhs.uk/commissioning/ccg-assess/clinical-priority-areas/

Scores for each indicator are aggregated and averaged, to give a total assessment score between 0 and 2. Each indicator has equal weight (25%).

When the data is shown:

Cancer metrics in the CCG IAF: One Year Survival Index (ONS); Proportion of all cancers diagnosed at stages 1 or 2 (NCRAS); Proportion of patients seen at hospital within 62 days after a GP referral for cancer (CWT); proportion of patients responding positively to overall patient experience question in the Cancer Patient Experience Survey (CPES)

More information about the data source:

This assessment is based on the published indicator values for the 4 indicators detailed below from the CCG IAF.

Data Source:

See "Interpretation Of Results" section

Data Period:

Assessment undertaken with latest data available as of July 2017

Further Information:

Further information on the purpose, background and construction of this indicator is at https://www.england.nhs.uk/commissioning/ccg-assess/clinical-priority-areas/

Method of data analysis

The methodology used to calculate an overall assessment rating is described in detail at: https://www.england.nhs.uk/commissioning/ccg-assess/clinical-priority-areas/

The panel has agreed the assessments and wording used to describe them. The summative assessment for cancer is based on four indicators (Early diagnosis, One year survival, 62 day wait after referral, and overall patient experience). On each of these indicators, CCGs have scores between 0 and 2 using a set of criteria agreed by the assessment panel. These criteria include comparison to national average performance (overall patient experience), an existing operational standard (62 day wait), and trajectory to the ambition set by the Cancer taskforce report (early diagnosis and one year survival). The panel has also agreed the minimum thresholds for CCGs to achieve a given asessment category. In the summative assessment a CCG will be:

• In box 1 (outstanding): if the overall assessment score is greater or equal than 1.3 • In box 2 (good): if the overall assessment score is greater or equal than 0.7 and less than 1.3 • In box 3 (requires improvement): if the overall assessment score is greater or equal than 0.3 and less than 0.7 • In box 4 (inadequate): if the overall assessment score is less than 0.3